{"id":10079,"date":"2024-10-28T17:03:30","date_gmt":"2024-10-28T09:03:30","guid":{"rendered":"https:\/\/flcube.com\/?p=10079"},"modified":"2024-11-13T23:07:11","modified_gmt":"2024-11-13T15:07:11","slug":"lanova-medicines-regains-rights-to-claudin-18-2-targeting-adc-lm-302-from-bms","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=10079","title":{"rendered":"LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS"},"content":{"rendered":"\n

LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the reclamation of control over LM-302, an antibody drug conjugate (ADC) targeting Claudin 18.2, from US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY<\/a>). LaNova had previously signed an agreement with Turning Point Therapeutics, Inc. (TPTX.US) in May 2022 to out-license LM-302. Turning Point paid an upfront fee of USD 25 million and was eligible for potential milestone payments of up to USD 1 billion to secure exclusive development and commercialization rights to the drug outside of Greater China and South Korea. BMS acquired Turning Point in June 2022, thereby acquiring its portfolio, including the ROS1\/NTRK\/ALK multi-target tyrosine kinase inhibitor (TKI) repotrectinib and LM-302.<\/p>\n\n\n\n

While BMS has not disclosed the reasons for returning the rights to LM-302, it has been speculated that the company may have lost competitive ground in the CLDN18.2 landscape. This comes on the heels of Astellas Pharma Inc. (TYO: 4503<\/a>)’s Vyloy (zolbetuximab-clzb), the first and only CLDN18.2-targeted therapy globally, receiving marketing approval in the US for use in combination with fluoropyrimidine- and platinum-containing chemotherapy in first-line locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative, CLDN18.2 positive, gastric or gastroesophageal junction (GEJ) adenocarcinoma.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the reclamation of control…<\/p>\n","protected":false},"author":1,"featured_media":10080,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[35,353,429,428,16,1376,849,1718,33,1177],"class_list":["post-10079","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-adc-xdc","tag-astellas-pharma","tag-bms","tag-bristol-myers-squibb","tag-cancer","tag-lanova-medicines","tag-nyse-bmy","tag-point-therapeutics","tag-tkis-egfr-vegf-btk-etc","tag-tyo-4503"],"yoast_head":"\nLaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the reclamation of control over LM-302, an antibody drug conjugate (ADC) targeting Claudin 18.2, from US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY). LaNova had previously signed an agreement with Turning Point Therapeutics, Inc. (TPTX.US) in May 2022 to out-license LM-302. Turning Point paid an upfront fee of USD 25 million and was eligible for potential milestone payments of up to USD 1 billion to secure exclusive development and commercialization rights to the drug outside of Greater China and South Korea. BMS acquired Turning Point in June 2022, thereby acquiring its portfolio, including the ROS1\/NTRK\/ALK multi-target tyrosine kinase inhibitor (TKI) repotrectinib and LM-302.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=10079\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=10079\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-28T09:03:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-13T15:07:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/faf2158174f94cafabc7ac0a4ef53b11.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"813\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10079#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10079\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS\",\"datePublished\":\"2024-10-28T09:03:30+00:00\",\"dateModified\":\"2024-11-13T15:07:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10079\"},\"wordCount\":213,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10079#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/faf2158174f94cafabc7ac0a4ef53b11.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Astellas Pharma\",\"BMS\",\"Bristol-Myers Squibb\",\"Cancer\",\"LaNova Medicines\",\"NYSE: BMY\",\"Point Therapeutics\",\"TKIs (EGFR VEGF BTK etc.)\",\"TYO: 4503\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=10079#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10079\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=10079\",\"name\":\"LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10079#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10079#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/faf2158174f94cafabc7ac0a4ef53b11.webp\",\"datePublished\":\"2024-10-28T09:03:30+00:00\",\"dateModified\":\"2024-11-13T15:07:11+00:00\",\"description\":\"LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the reclamation of control over LM-302, an antibody drug conjugate (ADC) targeting Claudin 18.2, from US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY). LaNova had previously signed an agreement with Turning Point Therapeutics, Inc. (TPTX.US) in May 2022 to out-license LM-302. Turning Point paid an upfront fee of USD 25 million and was eligible for potential milestone payments of up to USD 1 billion to secure exclusive development and commercialization rights to the drug outside of Greater China and South Korea. BMS acquired Turning Point in June 2022, thereby acquiring its portfolio, including the ROS1\\\/NTRK\\\/ALK multi-target tyrosine kinase inhibitor (TKI) repotrectinib and LM-302.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10079#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=10079\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10079#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/faf2158174f94cafabc7ac0a4ef53b11.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/faf2158174f94cafabc7ac0a4ef53b11.webp\",\"width\":1920,\"height\":813,\"caption\":\"LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10079#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS - Insight, China's Pharmaceutical Industry","description":"LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the reclamation of control over LM-302, an antibody drug conjugate (ADC) targeting Claudin 18.2, from US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY). LaNova had previously signed an agreement with Turning Point Therapeutics, Inc. (TPTX.US) in May 2022 to out-license LM-302. Turning Point paid an upfront fee of USD 25 million and was eligible for potential milestone payments of up to USD 1 billion to secure exclusive development and commercialization rights to the drug outside of Greater China and South Korea. BMS acquired Turning Point in June 2022, thereby acquiring its portfolio, including the ROS1\/NTRK\/ALK multi-target tyrosine kinase inhibitor (TKI) repotrectinib and LM-302.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=10079","og_locale":"en_US","og_type":"article","og_title":"LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=10079","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-10-28T09:03:30+00:00","article_modified_time":"2024-11-13T15:07:11+00:00","og_image":[{"width":1920,"height":813,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/faf2158174f94cafabc7ac0a4ef53b11.webp","type":"image\/webp"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=10079#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=10079"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS","datePublished":"2024-10-28T09:03:30+00:00","dateModified":"2024-11-13T15:07:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=10079"},"wordCount":213,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=10079#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/faf2158174f94cafabc7ac0a4ef53b11.webp","keywords":["ADC \/ XDC","Astellas Pharma","BMS","Bristol-Myers Squibb","Cancer","LaNova Medicines","NYSE: BMY","Point Therapeutics","TKIs (EGFR VEGF BTK etc.)","TYO: 4503"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=10079#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=10079","url":"https:\/\/flcube.com\/?p=10079","name":"LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=10079#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=10079#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/faf2158174f94cafabc7ac0a4ef53b11.webp","datePublished":"2024-10-28T09:03:30+00:00","dateModified":"2024-11-13T15:07:11+00:00","description":"LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the reclamation of control over LM-302, an antibody drug conjugate (ADC) targeting Claudin 18.2, from US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY). LaNova had previously signed an agreement with Turning Point Therapeutics, Inc. (TPTX.US) in May 2022 to out-license LM-302. Turning Point paid an upfront fee of USD 25 million and was eligible for potential milestone payments of up to USD 1 billion to secure exclusive development and commercialization rights to the drug outside of Greater China and South Korea. BMS acquired Turning Point in June 2022, thereby acquiring its portfolio, including the ROS1\/NTRK\/ALK multi-target tyrosine kinase inhibitor (TKI) repotrectinib and LM-302.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=10079#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=10079"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=10079#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/faf2158174f94cafabc7ac0a4ef53b11.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/faf2158174f94cafabc7ac0a4ef53b11.webp","width":1920,"height":813,"caption":"LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=10079#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/faf2158174f94cafabc7ac0a4ef53b11.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10079"}],"version-history":[{"count":3,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10079\/revisions"}],"predecessor-version":[{"id":12541,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10079\/revisions\/12541"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/10080"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10079"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10079"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10079"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}